Commercial immunoassays in biomarkers studies: Researchers beware!

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 2, 2013, Pages 249-251

  Rifai, Nader ^a   Watson, Ian D ^b   Miller, Greg ^c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

DIAGNOSTIC TEST; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; REAGENT KITS, DIAGNOSTIC;

EID: 84875448780     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0015     Document Type: Editorial

References (6)

1. National Institutes of Health. Research Portfolio Online Reporting Tools (RePORT). http://report.nih.gov/. Accessed 2012 June.
2. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
3. Smith RD. Mass spectrometry in biomarker application: from untargeted discovery to targeted verification, and implications for platform convergence and clinical application. Clin Chem 2012;58:528-30.
4. Git A. A recipe for disaster. Nature 2012;484:429-40.
5. Linnet K, Boyd JC. Selection and analytical validation of methods - with statistical techniques. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz textbook of clinical chemistry and molecular methods. 5th ed. Philadelphia: Elsevier Saunders, 2012: 7-47.
6. Rozet E, Marini RD, Ziemons E, Boulanger B, Hubert P. Advances in validation, risk and uncertainty assessment of bioanalytical methods. J Pharm Biomed Anal 2011;55:848-58.